Related Experiment Video

Updated: Mar 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.3K

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects

Pavlos Msaouel1, Mateusz Opyrchal2, Angela Dispenzieri3,4

  • 1MD Anderson Cancer Center, Division of Cancer Medicine, 1400 Holcombe Blvd, Unit 0463, Houston, TX 77030, USA.

Current Cancer Drug Targets
|February 24, 2017
PubMed

Insights

Attenuated measles virus (MV-Edm) vaccine strains show promise as oncolytic agents, selectively targeting and destroying various cancer cells. Genetically engineered MV-Edm derivatives are advancing through clinical trials for multiple cancer types.

Area of Science:

  • Oncolytic virotherapy
  • Cancer research
  • Viral immunology

Background:

  • Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains exhibit selective oncolytic properties against diverse cancer types.
  • Genetically engineered MV-Edm derivatives, such as MV-CEA and MV-NIS viruses, are being investigated for their therapeutic potential.

Purpose of the Study:

  • To review the preclinical data supporting the clinical translation of MV-Edm strains.
  • To summarize the clinical outcomes of the MV-Edm oncolytic platform.
  • To discuss recent developments and future strategies for MV-Edm vector applications.

Main Methods:

  • Review of basic science and preclinical studies on MV-Edm.
  • Analysis of clinical trial data for MV-Edm derivatives.
  • Discussion of ongoing and future translational research.

Main Results:

  • MV-Edm strains demonstrate preferential infection and lysis of various cancer cells.
  • Clinical trials are evaluating MV-Edm derivatives against ovarian cancer, glioblastoma, multiple myeloma, mesothelioma, head and neck cancer, breast cancer, and MPNSTs.
  • Early clinical data suggest the potential of this oncolytic platform.

Conclusions:

  • MV-Edm strains represent a promising oncolytic platform with demonstrated preclinical efficacy.
  • Clinical translation is supported by robust basic and preclinical data.
  • Ongoing research focuses on further vector development and strategic clinical applications for enhanced cancer treatment.
Keywords:
Cancer gene therapyMV-CEAMV-NISmeasles virus clinical trialsoncolytic measlesvirotherapy

More Related Videos

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.9K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.4K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K